Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses.
Identifieur interne : 002344 ( Ncbi/Curation ); précédent : 002343; suivant : 002345Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses.
Auteurs : Qiaoli Li [République populaire de Chine] ; Zhenhuan Zhao ; Dihan Zhou ; Yaoqing Chen ; Wei Hong ; Luyang Cao ; Jingyi Yang ; Yan Zhang ; Wei Shi ; Zhijian Cao ; Yingliang Wu ; Huimin Yan ; Wenxin LiSource :
- Peptides [ 1873-5169 ] ; 2011.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Chiens, Concentration inhibitrice 50, Conception de médicament, Données de séquences moléculaires, Grippe humaine (anatomopathologie), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Humains, Liaison aux protéines, Lignée cellulaire, Morbillivirus (), Morbillivirus (physiologie), Pandémies (), Peptides antimicrobiens cationiques (), Peptides antimicrobiens cationiques (génétique), Peptides antimicrobiens cationiques (pharmacologie), Protéines de l'enveloppe virale (métabolisme), Pénétration virale (), Rougeole (anatomopathologie), Rougeole (traitement médicamenteux), Rougeole (virologie), Réplication virale (), Scorpions (), Scorpions (génétique), Scorpions (métabolisme), Sous-type H5N1 du virus de la grippe A (), Sous-type H5N1 du virus de la grippe A (physiologie), Syndrome respiratoire aigu sévère (anatomopathologie), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Séquence d'acides aminés, Venins de scorpion (), Venins de scorpion (génétique), Venins de scorpion (métabolisme), Virus du SRAS (), Virus du SRAS (physiologie).
- MESH :
- anatomopathologie : Grippe humaine, Rougeole, Syndrome respiratoire aigu sévère.
- génétique : Peptides antimicrobiens cationiques, Scorpions, Venins de scorpion.
- métabolisme : Protéines de l'enveloppe virale, Scorpions, Venins de scorpion.
- pharmacologie : Antiviraux, Peptides antimicrobiens cationiques.
- physiologie : Morbillivirus, Sous-type H5N1 du virus de la grippe A, Virus du SRAS.
- traitement médicamenteux : Grippe humaine, Rougeole, Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux.
- virologie : Grippe humaine, Rougeole, Syndrome respiratoire aigu sévère.
- Animaux, Chiens, Concentration inhibitrice 50, Conception de médicament, Données de séquences moléculaires, Humains, Liaison aux protéines, Lignée cellulaire, Morbillivirus, Pandémies, Peptides antimicrobiens cationiques, Pénétration virale, Réplication virale, Scorpions, Sous-type H5N1 du virus de la grippe A, Séquence d'acides aminés, Venins de scorpion, Virus du SRAS.
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Antimicrobial Cationic Peptides (chemistry), Antimicrobial Cationic Peptides (genetics), Antimicrobial Cationic Peptides (pharmacology), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Cell Line, Dogs, Drug Design, Humans, Influenza A Virus, H5N1 Subtype (drug effects), Influenza A Virus, H5N1 Subtype (physiology), Influenza, Human (drug therapy), Influenza, Human (pathology), Influenza, Human (virology), Inhibitory Concentration 50, Measles (drug therapy), Measles (pathology), Measles (virology), Molecular Sequence Data, Morbillivirus (drug effects), Morbillivirus (physiology), Pandemics (prevention & control), Protein Binding, SARS Virus (drug effects), SARS Virus (physiology), Scorpion Venoms (chemistry), Scorpion Venoms (genetics), Scorpion Venoms (metabolism), Scorpions (chemistry), Scorpions (genetics), Scorpions (metabolism), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (pathology), Severe Acute Respiratory Syndrome (virology), Viral Envelope Proteins (metabolism), Virus Internalization (drug effects), Virus Replication (drug effects).
- MESH :
- chemical , chemistry : Antimicrobial Cationic Peptides, Scorpion Venoms.
- chemical , genetics : Antimicrobial Cationic Peptides, Scorpion Venoms.
- chemical , metabolism : Scorpion Venoms, Viral Envelope Proteins.
- chemical , pharmacology : Antimicrobial Cationic Peptides, Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents.
- chemistry : Scorpions.
- drug effects : Influenza A Virus, H5N1 Subtype, Morbillivirus, SARS Virus, Virus Internalization, Virus Replication.
- drug therapy : Influenza, Human, Measles, Severe Acute Respiratory Syndrome.
- genetics : Scorpions.
- metabolism : Scorpions.
- pathology : Influenza, Human, Measles, Severe Acute Respiratory Syndrome.
- physiology : Influenza A Virus, H5N1 Subtype, Morbillivirus, SARS Virus.
- prevention & control : Pandemics.
- virology : Influenza, Human, Measles, Severe Acute Respiratory Syndrome.
- Amino Acid Sequence, Animals, Cell Line, Dogs, Drug Design, Humans, Inhibitory Concentration 50, Molecular Sequence Data, Protein Binding.
Abstract
Outbreaks of SARS-CoV, influenza A (H5N1, H1N1) and measles viruses in recent years have raised serious concerns about the measures available to control emerging and re-emerging infectious viral diseases. Effective antiviral agents are lacking that specifically target RNA viruses such as measles, SARS-CoV and influenza H5N1 viruses, and available vaccinations have demonstrated variable efficacy. Therefore, the development of novel antiviral agents is needed to close the vaccination gap and silence outbreaks. We previously identified mucroporin, a cationic host defense peptide from scorpion venom, which can effectively inhibit standard bacteria. The optimized mucroporin-M1 can inhibit gram-positive bacteria at low concentrations and antibiotic-resistant pathogens. In this investigation, we further tested mucroporin and the optimized mucroporin-M1 for their antiviral activity. Surprisingly, we found that the antiviral activities of mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses were notably increased with an EC₅₀ of 7.15 μg/ml (3.52 μM) and a CC₅₀ of 70.46 μg/ml (34.70 μM) against measles virus, an EC₅₀ of 14.46 μg/ml (7.12 μM) against SARS-CoV and an EC₅₀ of 2.10 μg/ml (1.03 μM) against H5N1, while the original peptide mucroporin showed no antiviral activity against any of these three viruses. The inhibition model could be via a direct interaction with the virus envelope, thereby decreasing the infectivity of virus. This report provides evidence that host defense peptides from scorpion venom can be modified for antiviral activity by rational design and represents a practical approach for developing broad-spectrum antiviral agents, especially against RNA viruses.
DOI: 10.1016/j.peptides.2011.05.015
PubMed: 21620914
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001507
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001507
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001403
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002344
Links to Exploration step
pubmed:21620914Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses.</title>
<author><name sortKey="Li, Qiaoli" sort="Li, Qiaoli" uniqKey="Li Q" first="Qiaoli" last="Li">Qiaoli Li</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071</wicri:regionArea>
<placeName><settlement type="city">Wuhan</settlement>
<region type="région">Hubei</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhao, Zhenhuan" sort="Zhao, Zhenhuan" uniqKey="Zhao Z" first="Zhenhuan" last="Zhao">Zhenhuan Zhao</name>
</author>
<author><name sortKey="Zhou, Dihan" sort="Zhou, Dihan" uniqKey="Zhou D" first="Dihan" last="Zhou">Dihan Zhou</name>
</author>
<author><name sortKey="Chen, Yaoqing" sort="Chen, Yaoqing" uniqKey="Chen Y" first="Yaoqing" last="Chen">Yaoqing Chen</name>
</author>
<author><name sortKey="Hong, Wei" sort="Hong, Wei" uniqKey="Hong W" first="Wei" last="Hong">Wei Hong</name>
</author>
<author><name sortKey="Cao, Luyang" sort="Cao, Luyang" uniqKey="Cao L" first="Luyang" last="Cao">Luyang Cao</name>
</author>
<author><name sortKey="Yang, Jingyi" sort="Yang, Jingyi" uniqKey="Yang J" first="Jingyi" last="Yang">Jingyi Yang</name>
</author>
<author><name sortKey="Zhang, Yan" sort="Zhang, Yan" uniqKey="Zhang Y" first="Yan" last="Zhang">Yan Zhang</name>
</author>
<author><name sortKey="Shi, Wei" sort="Shi, Wei" uniqKey="Shi W" first="Wei" last="Shi">Wei Shi</name>
</author>
<author><name sortKey="Cao, Zhijian" sort="Cao, Zhijian" uniqKey="Cao Z" first="Zhijian" last="Cao">Zhijian Cao</name>
</author>
<author><name sortKey="Wu, Yingliang" sort="Wu, Yingliang" uniqKey="Wu Y" first="Yingliang" last="Wu">Yingliang Wu</name>
</author>
<author><name sortKey="Yan, Huimin" sort="Yan, Huimin" uniqKey="Yan H" first="Huimin" last="Yan">Huimin Yan</name>
</author>
<author><name sortKey="Li, Wenxin" sort="Li, Wenxin" uniqKey="Li W" first="Wenxin" last="Li">Wenxin Li</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21620914</idno>
<idno type="pmid">21620914</idno>
<idno type="doi">10.1016/j.peptides.2011.05.015</idno>
<idno type="wicri:Area/PubMed/Corpus">001507</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001507</idno>
<idno type="wicri:Area/PubMed/Curation">001507</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001507</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001403</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001403</idno>
<idno type="wicri:Area/Ncbi/Merge">002344</idno>
<idno type="wicri:Area/Ncbi/Curation">002344</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses.</title>
<author><name sortKey="Li, Qiaoli" sort="Li, Qiaoli" uniqKey="Li Q" first="Qiaoli" last="Li">Qiaoli Li</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071</wicri:regionArea>
<placeName><settlement type="city">Wuhan</settlement>
<region type="région">Hubei</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zhao, Zhenhuan" sort="Zhao, Zhenhuan" uniqKey="Zhao Z" first="Zhenhuan" last="Zhao">Zhenhuan Zhao</name>
</author>
<author><name sortKey="Zhou, Dihan" sort="Zhou, Dihan" uniqKey="Zhou D" first="Dihan" last="Zhou">Dihan Zhou</name>
</author>
<author><name sortKey="Chen, Yaoqing" sort="Chen, Yaoqing" uniqKey="Chen Y" first="Yaoqing" last="Chen">Yaoqing Chen</name>
</author>
<author><name sortKey="Hong, Wei" sort="Hong, Wei" uniqKey="Hong W" first="Wei" last="Hong">Wei Hong</name>
</author>
<author><name sortKey="Cao, Luyang" sort="Cao, Luyang" uniqKey="Cao L" first="Luyang" last="Cao">Luyang Cao</name>
</author>
<author><name sortKey="Yang, Jingyi" sort="Yang, Jingyi" uniqKey="Yang J" first="Jingyi" last="Yang">Jingyi Yang</name>
</author>
<author><name sortKey="Zhang, Yan" sort="Zhang, Yan" uniqKey="Zhang Y" first="Yan" last="Zhang">Yan Zhang</name>
</author>
<author><name sortKey="Shi, Wei" sort="Shi, Wei" uniqKey="Shi W" first="Wei" last="Shi">Wei Shi</name>
</author>
<author><name sortKey="Cao, Zhijian" sort="Cao, Zhijian" uniqKey="Cao Z" first="Zhijian" last="Cao">Zhijian Cao</name>
</author>
<author><name sortKey="Wu, Yingliang" sort="Wu, Yingliang" uniqKey="Wu Y" first="Yingliang" last="Wu">Yingliang Wu</name>
</author>
<author><name sortKey="Yan, Huimin" sort="Yan, Huimin" uniqKey="Yan H" first="Huimin" last="Yan">Huimin Yan</name>
</author>
<author><name sortKey="Li, Wenxin" sort="Li, Wenxin" uniqKey="Li W" first="Wenxin" last="Li">Wenxin Li</name>
</author>
</analytic>
<series><title level="j">Peptides</title>
<idno type="eISSN">1873-5169</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Antimicrobial Cationic Peptides (chemistry)</term>
<term>Antimicrobial Cationic Peptides (genetics)</term>
<term>Antimicrobial Cationic Peptides (pharmacology)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Cell Line</term>
<term>Dogs</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Influenza A Virus, H5N1 Subtype (drug effects)</term>
<term>Influenza A Virus, H5N1 Subtype (physiology)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (pathology)</term>
<term>Influenza, Human (virology)</term>
<term>Inhibitory Concentration 50</term>
<term>Measles (drug therapy)</term>
<term>Measles (pathology)</term>
<term>Measles (virology)</term>
<term>Molecular Sequence Data</term>
<term>Morbillivirus (drug effects)</term>
<term>Morbillivirus (physiology)</term>
<term>Pandemics (prevention & control)</term>
<term>Protein Binding</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Scorpion Venoms (chemistry)</term>
<term>Scorpion Venoms (genetics)</term>
<term>Scorpion Venoms (metabolism)</term>
<term>Scorpions (chemistry)</term>
<term>Scorpions (genetics)</term>
<term>Scorpions (metabolism)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (pathology)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Viral Envelope Proteins (metabolism)</term>
<term>Virus Internalization (drug effects)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Chiens</term>
<term>Concentration inhibitrice 50</term>
<term>Conception de médicament</term>
<term>Données de séquences moléculaires</term>
<term>Grippe humaine (anatomopathologie)</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Grippe humaine (virologie)</term>
<term>Humains</term>
<term>Liaison aux protéines</term>
<term>Lignée cellulaire</term>
<term>Morbillivirus ()</term>
<term>Morbillivirus (physiologie)</term>
<term>Pandémies ()</term>
<term>Peptides antimicrobiens cationiques ()</term>
<term>Peptides antimicrobiens cationiques (génétique)</term>
<term>Peptides antimicrobiens cationiques (pharmacologie)</term>
<term>Protéines de l'enveloppe virale (métabolisme)</term>
<term>Pénétration virale ()</term>
<term>Rougeole (anatomopathologie)</term>
<term>Rougeole (traitement médicamenteux)</term>
<term>Rougeole (virologie)</term>
<term>Réplication virale ()</term>
<term>Scorpions ()</term>
<term>Scorpions (génétique)</term>
<term>Scorpions (métabolisme)</term>
<term>Sous-type H5N1 du virus de la grippe A ()</term>
<term>Sous-type H5N1 du virus de la grippe A (physiologie)</term>
<term>Syndrome respiratoire aigu sévère (anatomopathologie)</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Séquence d'acides aminés</term>
<term>Venins de scorpion ()</term>
<term>Venins de scorpion (génétique)</term>
<term>Venins de scorpion (métabolisme)</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antimicrobial Cationic Peptides</term>
<term>Scorpion Venoms</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antimicrobial Cationic Peptides</term>
<term>Scorpion Venoms</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Scorpion Venoms</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antimicrobial Cationic Peptides</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Rougeole</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Scorpions</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
<term>Morbillivirus</term>
<term>SARS Virus</term>
<term>Virus Internalization</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
<term>Measles</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Scorpions</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Peptides antimicrobiens cationiques</term>
<term>Scorpions</term>
<term>Venins de scorpion</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Scorpions</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Protéines de l'enveloppe virale</term>
<term>Scorpions</term>
<term>Venins de scorpion</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Influenza, Human</term>
<term>Measles</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Peptides antimicrobiens cationiques</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Morbillivirus</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term>
<term>Morbillivirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Pandemics</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
<term>Rougeole</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Rougeole</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
<term>Measles</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Cell Line</term>
<term>Dogs</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Inhibitory Concentration 50</term>
<term>Molecular Sequence Data</term>
<term>Protein Binding</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Chiens</term>
<term>Concentration inhibitrice 50</term>
<term>Conception de médicament</term>
<term>Données de séquences moléculaires</term>
<term>Humains</term>
<term>Liaison aux protéines</term>
<term>Lignée cellulaire</term>
<term>Morbillivirus</term>
<term>Pandémies</term>
<term>Peptides antimicrobiens cationiques</term>
<term>Pénétration virale</term>
<term>Réplication virale</term>
<term>Scorpions</term>
<term>Sous-type H5N1 du virus de la grippe A</term>
<term>Séquence d'acides aminés</term>
<term>Venins de scorpion</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Outbreaks of SARS-CoV, influenza A (H5N1, H1N1) and measles viruses in recent years have raised serious concerns about the measures available to control emerging and re-emerging infectious viral diseases. Effective antiviral agents are lacking that specifically target RNA viruses such as measles, SARS-CoV and influenza H5N1 viruses, and available vaccinations have demonstrated variable efficacy. Therefore, the development of novel antiviral agents is needed to close the vaccination gap and silence outbreaks. We previously identified mucroporin, a cationic host defense peptide from scorpion venom, which can effectively inhibit standard bacteria. The optimized mucroporin-M1 can inhibit gram-positive bacteria at low concentrations and antibiotic-resistant pathogens. In this investigation, we further tested mucroporin and the optimized mucroporin-M1 for their antiviral activity. Surprisingly, we found that the antiviral activities of mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses were notably increased with an EC₅₀ of 7.15 μg/ml (3.52 μM) and a CC₅₀ of 70.46 μg/ml (34.70 μM) against measles virus, an EC₅₀ of 14.46 μg/ml (7.12 μM) against SARS-CoV and an EC₅₀ of 2.10 μg/ml (1.03 μM) against H5N1, while the original peptide mucroporin showed no antiviral activity against any of these three viruses. The inhibition model could be via a direct interaction with the virus envelope, thereby decreasing the infectivity of virus. This report provides evidence that host defense peptides from scorpion venom can be modified for antiviral activity by rational design and represents a practical approach for developing broad-spectrum antiviral agents, especially against RNA viruses.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002344 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002344 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:21620914 |texte= Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:21620914" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |